AbCellera Biologics (ABCL) Competitors

$4.09 -0.31 (-7.05%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$4.12 +0.03 (+0.73%)

As of 05/15/2026 07:59 PM Eastern

ABCL vs. PTGX, BLTE, CGON, TERN, and PTCT

Should you buy AbCellera Biologics stock or one of its competitors? MarketBeat compares AbCellera Biologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AbCellera Biologics include Protagonist Therapeutics (PTGX), Belite Bio (BLTE), CG Oncology (CGON), Terns Pharmaceuticals (TERN), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry.

How does AbCellera Biologics compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Protagonist Therapeutics presently has a consensus target price of $113.69, suggesting a potential upside of 11.27%. AbCellera Biologics has a consensus target price of $7.80, suggesting a potential upside of 90.71%. Given AbCellera Biologics' higher probable upside, analysts clearly believe AbCellera Biologics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Protagonist Therapeutics has a net margin of -154.88% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
AbCellera Biologics	-181.75%	-14.86%	-10.62%

In the previous week, Protagonist Therapeutics had 4 more articles in the media than AbCellera Biologics. MarketBeat recorded 15 mentions for Protagonist Therapeutics and 11 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.49 beat Protagonist Therapeutics' score of 0.22 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AbCellera Biologics	0 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Protagonist Therapeutics has higher earnings, but lower revenue than AbCellera Biologics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	142.79	-$130.15M	-$1.81	N/A
AbCellera Biologics	$75.13M	16.62	-$146.41M	-$0.48	N/A

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Protagonist Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market.

Summary

AbCellera Biologics beats Protagonist Therapeutics on 9 of the 17 factors compared between the two stocks.

How does AbCellera Biologics compare to Belite Bio?

AbCellera Biologics (NASDAQ:ABCL) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

AbCellera Biologics currently has a consensus target price of $7.80, indicating a potential upside of 90.71%. Belite Bio has a consensus target price of $202.33, indicating a potential upside of 41.49%. Given AbCellera Biologics' stronger consensus rating and higher possible upside, analysts plainly believe AbCellera Biologics is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Belite Bio has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-181.75%	-14.86%	-10.62%
Belite Bio	N/A	-19.49%	-19.05%

In the previous week, AbCellera Biologics had 4 more articles in the media than Belite Bio. MarketBeat recorded 11 mentions for AbCellera Biologics and 7 mentions for Belite Bio. AbCellera Biologics' average media sentiment score of 0.49 beat Belite Bio's score of 0.42 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	0 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Belite Bio has lower revenue, but higher earnings than AbCellera Biologics. Belite Bio is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	16.62	-$146.41M	-$0.48	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.30	N/A

61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 28.4% of AbCellera Biologics shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

AbCellera Biologics has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.19, suggesting that its share price is 219% less volatile than the broader market.

Summary

AbCellera Biologics beats Belite Bio on 13 of the 16 factors compared between the two stocks.

How does AbCellera Biologics compare to CG Oncology?

AbCellera Biologics (NASDAQ:ABCL) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 28.4% of AbCellera Biologics shares are owned by insiders. Comparatively, 4.8% of CG Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

AbCellera Biologics currently has a consensus target price of $7.80, indicating a potential upside of 90.71%. CG Oncology has a consensus target price of $81.73, indicating a potential upside of 22.11%. Given AbCellera Biologics' higher possible upside, analysts plainly believe AbCellera Biologics is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

AbCellera Biologics has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	16.62	-$146.41M	-$0.48	N/A
CG Oncology	$4.04M	1,461.19	-$160.99M	-$2.33	N/A

AbCellera Biologics has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market.

In the previous week, CG Oncology had 22 more articles in the media than AbCellera Biologics. MarketBeat recorded 33 mentions for CG Oncology and 11 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.49 beat CG Oncology's score of 0.24 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	0 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CG Oncology	6 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

CG Oncology has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-181.75%	-14.86%	-10.62%
CG Oncology	N/A	-23.33%	-22.24%

Summary

AbCellera Biologics beats CG Oncology on 12 of the 17 factors compared between the two stocks.

How does AbCellera Biologics compare to Terns Pharmaceuticals?

AbCellera Biologics (NASDAQ:ABCL) and Terns Pharmaceuticals (NASDAQ:TERN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 98.3% of Terns Pharmaceuticals shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by insiders. Comparatively, 1.5% of Terns Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

AbCellera Biologics presently has a consensus target price of $7.80, indicating a potential upside of 90.71%. Terns Pharmaceuticals has a consensus target price of $55.14, indicating a potential upside of 4.13%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, equities analysts clearly believe AbCellera Biologics is more favorable than Terns Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Terns Pharmaceuticals	1 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.27

Terns Pharmaceuticals has lower revenue, but higher earnings than AbCellera Biologics. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	16.62	-$146.41M	-$0.48	N/A
Terns Pharmaceuticals	N/A	N/A	-$96.21M	-$1.03	N/A

AbCellera Biologics has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market. Comparatively, Terns Pharmaceuticals has a beta of -0.37, meaning that its share price is 137% less volatile than the broader market.

In the previous week, AbCellera Biologics had 9 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 11 mentions for AbCellera Biologics and 2 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 1.35 beat AbCellera Biologics' score of 0.49 indicating that Terns Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	0 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Terns Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Terns Pharmaceuticals has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Terns Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-181.75%	-14.86%	-10.62%
Terns Pharmaceuticals	N/A	-20.02%	-19.37%

Summary

AbCellera Biologics beats Terns Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does AbCellera Biologics compare to PTC Therapeutics?

AbCellera Biologics (NASDAQ:ABCL) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

In the previous week, AbCellera Biologics and AbCellera Biologics both had 11 articles in the media. AbCellera Biologics' average media sentiment score of 0.49 beat PTC Therapeutics' score of 0.43 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	0 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PTC Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PTC Therapeutics has a net margin of -22.58% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-181.75%	-14.86%	-10.62%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

AbCellera Biologics has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

PTC Therapeutics has higher revenue and earnings than AbCellera Biologics. PTC Therapeutics is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	16.62	-$146.41M	-$0.48	N/A
PTC Therapeutics	$1.73B	3.43	$682.64M	-$2.33	N/A

61.4% of AbCellera Biologics shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

AbCellera Biologics presently has a consensus target price of $7.80, indicating a potential upside of 90.71%. PTC Therapeutics has a consensus target price of $88.36, indicating a potential upside of 23.63%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, equities analysts clearly believe AbCellera Biologics is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
PTC Therapeutics	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.57

Summary

AbCellera Biologics beats PTC Therapeutics on 10 of the 15 factors compared between the two stocks.

Get AbCellera Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABCL vs. The Competition

Export

Metric	AbCellera Biologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.25B	$3.31B	$6.38B	$12.30B
Dividend Yield	N/A	2.35%	2.81%	5.27%
P/E Ratio	-8.52	18.50	20.66	25.27
Price / Sales	16.62	284.70	551.98	75.61
Price / Cash	N/A	121.77	42.43	54.86
Price / Book	1.33	6.63	9.87	6.90
Net Income	-$146.41M	$24.40M	$3.57B	$334.66M
7 Day Performance	-21.95%	4.14%	0.23%	0.12%
1 Month Performance	2.00%	-4.80%	-2.54%	-0.18%
1 Year Performance	101.48%	62.87%	33.54%	30.62%

AbCellera Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABCL AbCellera Biologics	3.0289 of 5 stars	$4.09 -7.0%	$7.80 +90.7%	+101.5%	$1.25B	$75.13M	N/A	500	News Coverage Earnings Report Analyst Downgrade
PTGX Protagonist Therapeutics	1.9061 of 5 stars	$99.36 +0.5%	$113.69 +14.4%	+129.7%	$6.39B	$46.02M	N/A	120	News Coverage Insider Trade
BLTE Belite Bio	2.652 of 5 stars	$154.88 -0.7%	$202.33 +30.6%	+122.0%	$6.19B	N/A	N/A	10	Upcoming Earnings
CGON CG Oncology	2.4869 of 5 stars	$69.62 +0.6%	$79.55 +14.3%	+163.2%	$6.13B	$4.04M	N/A	61	Positive News Earnings Report Analyst Forecast Analyst Revision
TERN Terns Pharmaceuticals	2.1372 of 5 stars	$52.95 flat	$55.14 +4.1%	+1,738.5%	$6.12B	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABCL) was last updated on 5/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbCellera Biologics (ABCL) Competitors

ABCL vs. PTGX, BLTE, CGON, TERN, and PTCT

How does AbCellera Biologics compare to Protagonist Therapeutics?

Summary

How does AbCellera Biologics compare to Belite Bio?

Summary

How does AbCellera Biologics compare to CG Oncology?

Summary

How does AbCellera Biologics compare to Terns Pharmaceuticals?

Summary

How does AbCellera Biologics compare to PTC Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL vs. The Competition

AbCellera Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AbCellera Biologics (ABCL) Competitors

ABCL vs. PTGX, BLTE, CGON, TERN, and PTCT

How does AbCellera Biologics compare to Protagonist Therapeutics?

Do analysts prefer PTGX or ABCL?

Is PTGX or ABCL more profitable?

Does the media prefer PTGX or ABCL?

Which has higher earnings & valuation, PTGX or ABCL?

Do institutionals and insiders hold more shares of PTGX or ABCL?

Which has more volatility and risk, PTGX or ABCL?

Summary

How does AbCellera Biologics compare to Belite Bio?

Do analysts recommend ABCL or BLTE?

Is ABCL or BLTE more profitable?

Does the media favor ABCL or BLTE?

Which has better valuation & earnings, ABCL or BLTE?

Do insiders & institutionals believe in ABCL or BLTE?

Which has more risk & volatility, ABCL or BLTE?

Summary

How does AbCellera Biologics compare to CG Oncology?

Do insiders & institutionals believe in ABCL or CGON?

Do analysts recommend ABCL or CGON?

Which has better valuation & earnings, ABCL or CGON?

Which has more risk & volatility, ABCL or CGON?

Does the media favor ABCL or CGON?

Is ABCL or CGON more profitable?

Summary

How does AbCellera Biologics compare to Terns Pharmaceuticals?

Do institutionals & insiders hold more shares of ABCL or TERN?

Do analysts rate ABCL or TERN?

Which has preferable valuation & earnings, ABCL or TERN?

Which has more volatility & risk, ABCL or TERN?

Does the media favor ABCL or TERN?

Is ABCL or TERN more profitable?

Summary

How does AbCellera Biologics compare to PTC Therapeutics?

Does the media favor ABCL or PTCT?

Is ABCL or PTCT more profitable?

Which has more volatility & risk, ABCL or PTCT?

Which has preferable valuation & earnings, ABCL or PTCT?

Do institutionals & insiders hold more shares of ABCL or PTCT?

Do analysts rate ABCL or PTCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL vs. The Competition

AbCellera Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools